Ectopic bone formation with the help of growth factor bFGF.
Wiltfang J., Merten HA., Wiltfang J.
Animal Study, published in J Craniomaxillofac Surg (1996) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Craniomaxillofac Surg (1996)
- Country
- Scotland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 8938513
- DOI
- 10.1016/s1010-5182(96)80063-1
Abstract (original English)
In the present study, basic fibroblast growth factor and a non-resorbable biological matrix (Endobon) were used to help to induce ectopic bone formation in the subdermal fatty tissue of the Göttingen miniature pig. In the early phase, bFGF improved the recipient conditions by enhancing angioneogenesis and helping to provide pluripotent mesenchymal cells. However, vitally transplanted bone cells were necessary in order to ensure successful bone formation. The Endobon only served as an osteoconductive matrix.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.